Medication nonadherence patterns among children with epilepsy associated with socioeconomic status

April 26, 2011 in Medications

An examination of medication adherence among children with newly diagnosed epilepsy found that nearly 60 percent showed persistent nonadherence during the first 6 months of therapy, and that lower socioeconomic status was associated with higher non-adherence, according to a study in the April 27 issue of JAMA.

Epilepsy, a disorder of recurrent unprovoked seizures, affects 325,000 children younger than 15 years in the United States. "Because of epilepsy's common occurrence, the narrow therapeutic and safety margins of antiepileptic medications, and the recognized complications of medication non-adherence in adults with , identifying the rates, patterns, and predictors of non-adherence in children with epilepsy is imperative. The onset and evolution of antiepileptic drug nonadherence in children with newly diagnosed epilepsy remains unknown," according to background information in the article.

Avani C. Modi, Ph.D., of Cincinnati Children's Hospital Center, Cincinnati, and colleagues conducted a study to identify and characterize trajectories over the first 6 months of therapy for children with new-onset epilepsy using electronic monitors and to identify sociodemographic and epilepsy-specific predictors of adherence trajectories. The study included 124 children (2-12 years old) with final data collection through September 2009. Adherence was measured electronically with a system in which the cap of the medication bottle contained a microelectronic circuit to register the dates and times the bottle was opened and closed.

Of the children in the study, 58 percent demonstrated persistent nonadherence during the first 6 months of therapy. The researchers identified 5 different adherence patterns with group-based trajectory models. The 5 groups, based on severity and course of non-adherence, were severe early nonadherence (n= 16; 13 percent), severe delayed nonadherence (n = 8; 7 percent), moderate nonadherence (n= 16; 13 percent), mild nonadherence (n = 32; 26 percent), and near-perfect adherence (n = 52; 42 percent).

"The adherence pattern of most patients was established by the first month of therapy. was the sole predictor of adherence trajectory group status, with lower socioeconomic status associated with higher non-adherence," the authors write.

"Socioeconomic status was the only significant predictor of nonadherence and may help identify patients at highest risk. Given that nonadherence is frequent, may compromise the benefits of drug therapy, may complicate interpretation of clinical response, and can be addressed through evidence-based interventions, clinicians should consider routinely assessing adherence to antiepileptic drug therapy in all with ."

"…the rate of nonadherence over the course of the first 6 months of therapy is concerning and suggests a need for intervention studies that aim to optimize adherence early in the course of therapy," the researchers conclude.

More information: JAMA. 2011;305[16]1669-1676.

Provided by JAMA and Archives Journals search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts
  • A couple of questions about schizophrenia
    createdMay 17, 2012
  • Paralyzed woman uses thoughts to move robotic arm
    createdMay 17, 2012
  • Coffee Decreases Risk of Death
    createdMay 17, 2012
  • Understanding the mechanisms of disease .
    createdMay 14, 2012
  • Short burst of hypersensitivity disorder?
    createdMay 13, 2012
  • Copper aspirinate
    createdMay 12, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Generic versions of plavix approved

(HealthDay) -- The first generic versions of Plavix (clopidogrel bisulfate) have been approved by the U.S. Food and Drug Administration.

Medications created May 18, 2012 | popularity not rated yet | comments 0

'Last resort' antibiotics increasingly used to fight multidrug-resistant bugs

Multidrug-resistant pathogens are becoming more frequent, and the few "last resort" treatments available for infections with these bacteria have also shown an increase in use in recent years, according to a study published ...

Medications created May 16, 2012 | popularity not rated yet | comments 0

Study finds common antibiotic azithromycin carries heart risk

Vanderbilt researchers have discovered a rare, but important risk posed by the antibiotic azithromycin, commonly called a "Z-pack." The study found a 2.5-fold higher risk of death from cardiovascular death in the first five ...

Medications created May 16, 2012 | popularity not rated yet | comments 0 | with audio podcast

In drug-approval race, US FDA ahead of Canada, Europe

The U.S. Food and Drug Administration (FDA) generally approves drug therapies faster and earlier than its counterparts in Canada and Europe, according to a new study by Yale School of Medicine researchers. The study counters ...

Medications created May 16, 2012 | popularity not rated yet | comments 0 | with audio podcast

Too many drugs for many older patients

Older patients are increasingly prescribed multiple drugs that, when combined, can lead to negative side effects and poor health outcomes.  A new Cochrane Library evidence review reveals that little is kno ...

Medications created May 16, 2012 | popularity not rated yet | comments 0


Growth factor in stem cells may spur recovery from multiple sclerosis

A substance in human mesenchymal stem cells that promotes growth appears to spur restoration of nerves and their function in rodent models of multiple sclerosis (MS), researchers at Case Western Reserve University School ...

Creatine may protect liver from fatty diet

(Medical Xpress) -- A collaborative study involving researchers at the University of Alberta, the University of São Paulo in Brazil, and the Memorial University of Newfoundland has shown that creatine, ...

Is the U.S. ready for home HIV tests?

At the pharmacy, you can buy anything from tea kettles to Tylenol. But what if you could buy a rapid HIV test over the counter and test yourself in the privacy of your own home?

New drug shrinks brain tumours in melanoma patients

(Medical Xpress) -- Australian researchers have reported promising results with a new drug that shrinks brain tumours in melanoma patients. Their findings are published in The Lancet medical journal today. ...

Stopping cell migration may help block fibrosis and the spread of cancer

(Medical Xpress) -- Discoveries by a Yale-led team of scientists could lead the way for development of new therapies for treating fibrosis and tumor metastasis. The researchers have both uncovered a signaling ...

Study debunks idea that foreign health aid rife with waste

(Medical Xpress) -- When a 2010 study concluded that about half the money given to international governments for providing health-care services isn’t used as intended, skeptics who argued that foreign aid is largely ...